• Home
  • Browse
    • Current Issue
    • By Issue
    • By Author
    • By Subject
    • Author Index
    • Keyword Index
  • Journal Info
    • About Journal
    • Aims and Scope
    • Editorial Board
    • Publication Ethics
    • Peer Review Process
  • Guide for Authors
  • Submit Manuscript
  • Contact Us
 
  • Login
  • Register
Home Articles List Article Information
  • Save Records
  • |
  • Printable Version
  • |
  • Recommend
  • |
  • How to cite Export to
    RIS EndNote BibTeX APA MLA Harvard Vancouver
  • |
  • Share Share
    CiteULike Mendeley Facebook Google LinkedIn Twitter
Research Journal of Applied Biotechnology
arrow Articles in Press
arrow Current Issue
Journal Archive
Volume Volume 11 (2025)
Volume Volume 10 (2024)
Issue Issue 2
Issue Issue 1
Volume Volume 9 (2023)
Volume Volume 8 (2022)
Volume Volume 7 (2021)
Volume Volume 6 (2020)
Volume Volume 5 (2019)
Volume Volume 4 (2018)
Volume Volume 3 (2017)
Volume Volume 2 (2016)
Volume Volume 1 (2015)
Saad, F., Daif, A., Sakr, M., Ismail, H. (2024). Gene Expression Analysis of ACE2, TMPRSS2, and LZTFL1 in COVID-19 Patients: a pilot study. Research Journal of Applied Biotechnology, 10(1), 1-14. doi: 10.21608/rjab.2024.248228.1045
Faten M. Saad; Ahmed Daif; Moustafa Sakr; Hisham Ismail. "Gene Expression Analysis of ACE2, TMPRSS2, and LZTFL1 in COVID-19 Patients: a pilot study". Research Journal of Applied Biotechnology, 10, 1, 2024, 1-14. doi: 10.21608/rjab.2024.248228.1045
Saad, F., Daif, A., Sakr, M., Ismail, H. (2024). 'Gene Expression Analysis of ACE2, TMPRSS2, and LZTFL1 in COVID-19 Patients: a pilot study', Research Journal of Applied Biotechnology, 10(1), pp. 1-14. doi: 10.21608/rjab.2024.248228.1045
Saad, F., Daif, A., Sakr, M., Ismail, H. Gene Expression Analysis of ACE2, TMPRSS2, and LZTFL1 in COVID-19 Patients: a pilot study. Research Journal of Applied Biotechnology, 2024; 10(1): 1-14. doi: 10.21608/rjab.2024.248228.1045

Gene Expression Analysis of ACE2, TMPRSS2, and LZTFL1 in COVID-19 Patients: a pilot study

Article 1, Volume 10, Issue 1, June 2024, Page 1-14  XML PDF (649.61 K)
Document Type: Original Article
DOI: 10.21608/rjab.2024.248228.1045
View on SCiNiTO View on SCiNiTO
Authors
Faten M. Saad1; Ahmed Daif2; Moustafa Sakr email orcid 1; Hisham Ismail1
1Molecular diagnostics and therapeutics department, Genetic Engineering and Biotechnology Research Institute (GEBRI), University of Sadat City, Egypt
21Molecular diagnostics and therapeutics department, Genetic Engineering and Biotechnology Research Institute (GEBRI), University of Sadat City, Egypt
Abstract
The objective of this research was to assess gene expression levels of ACE2, TMPRSS2, and LZTFL1 in COVID-19 patients from Egypt and investigate their potential association with the severity of the illness. The study involved ninety-six participants, divided into two groups: individuals experiencing severe COVID-19 symptoms and those with milder manifestations. Quantitative polymerase chain reaction (qRT-PCR) was employed to determine the gene expression levels of ACE2, TMPRSS2, and LZTFL1.
In the mild cases, the median age was 35 years, with an age range of 30-41 years, while severe cases had a median age of 65 years, ranging from 58 to 72 years. The male-to-female ratio in the entire group was 47.9% to 52.1%. All participants tested positive for COVID-19 based on nasal swab qPCR tests. Severe cases exhibit a significantly higher mean age. Comorbidities like type 2 diabetes (T2DM) and hypertension are markedly more prevalent in severe cases, while the absence of comorbidities is significantly associated with mild cases. The initial expression levels of all the examined genes were notably higher in severe COVID-19 patients compared to those with mild symptoms. The statistical significance was reflected in the p-values, which were less than 0.001 for ACE2, 0.05 for TMPRSS2, and 0.002 for LZTFL1. ROC curves were employed. The results showed that ACE2 exhibited greater sensitivity (89.58%) and specificity (79.17%) in predicting severe COVID-19 in comparison to LZTFL1 (70.83%) and TMPRSS2 (60.42%). These results propose that ACE2 expression may serve as a profitable prognostic marker for COVID-19.
Keywords
COVID 19; ACE2; TMPRSS2; LZTFL1
Statistics
Article View: 204
PDF Download: 189
Home | Glossary | News | Aims and Scope | Sitemap
Top Top

Journal Management System. Designed by NotionWave.